Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon Aug 18, 2023 6:25pm
219 Views
Post# 35595727

RE:RE:RE:RE:RE:RE:RE:share activity

RE:RE:RE:RE:RE:RE:RE:share activityThe last PP ending June 30 bought them 3-4 m of cash. So that means end of Oct. If they are in fact doing another one that should get them another 3-4 m (if they can get the same amount). I think the bet will be on getting some kind of license deal off of a BTD. If they don't get BTD they will have to go and beg for a JV at crazy bad terms for them.

If they are really really lucky and get BTD AND get a price run up then there are warrants expiring

3,157,059 at a price of $0.50 (until October 3, 2023)
That could bring in 1.5ish million in cash and get some more breathing room.

They really need a new way to get cash for a phase 2 clinical trial. This is nuts.

<< Previous
Bullboard Posts
Next >>